CMS has submitted its initial lower price offers to drug makers for the 10 Part-D drugs selected for the program’s inaugural round of price negotiations in Medicare, along with a justification of the agency’s price and decision-making, HHS said Thursday (Feb. 1), prompting outcry from the brand drug lobby that the price offers were made behind closed doors, are politically motivated and don’t account for the true value of drugs. Drug companies have until March 2 to either accept the...